NCT07485920

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The Affiliated Hospital of Qingdao University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, single-arm, multicenter, exploratory clinical trial. It aims to evaluate the efficacy and safety of tislelizumab combined with nintedanib as consolidation therapy for patients with limited-stage small cell lung cancer after concurrent chemoradiotherapy, and to explore the prognostic markers related to the therapeutic effect.

Conditions

• Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventions

Type	Name	Description
DRUG	Tislelizumab and nintedanib	Tislelizumab (200mgQ3W, D1) combined with nintedanib (150mg bid) until disease progression, death, or the occurrence of intolerable toxic reactions

Timeline

• Start date: 2026-05-01
• Primary completion: 2028-12-10
• Completion: 2030-01-31
• First posted: 2026-03-20
• Last updated: 2026-03-20

Locations

6 sites across 1 country: China